Samantha L Kendrick, PhD, MS

Research Program: Cancer Biology Faculty Rank: Associate Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Biochemistry & Molecular Biology

Cancer Research Interest

• Disease Site Focus: Leukemia/ Lymphoma
• Research Focus Area: Treatment, Carcinogenesis
• Type of Research: Basic

Contact Information

• Email Address: SKENDRICK@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• NIH/Nat. Cancer Institute – 1R25CA302439
  “Cancer and Developing Entrepreneurial Technologies (CADET)”
  Co-Investigator
  9/1/2025 – 8/31/2030
• American Cancer Society, Inc. – CAT-24-1374686-01-CAT
  “Impact of DNA topology on facilitating mutational events in lymphoma”
  Principal Investigator
  12/1/2024 – 5/31/2026
• National Science Foundation – 2341253
  “Replication of G-quadruplex DNA by translesion polymerases”
  Principal Investigator
  5/1/2024 – 4/30/2028
• US Department of Defense – W81XWH2211031
  “Targeting unique DNA structures to repress oncogenic signaling in lymphoma”
  Principal Investigator
  9/15/2022 – 9/14/2026
• NIH/Nat. Cancer Institute – 1R25CA250979
  “Partnership in Cancer Research (PCAR)”
  Principal Investigator
  9/1/2020 – 8/31/2026

Recent Publications

• Brown S, Swafford K, McCrury M, [et al., including Kendrick S]. G-quadruplex and i-motif DNA structures form in the promoter of the key innate immune adaptor MYD88. Cell reports. Physical science. 2025 6(5). PMID: 40642110.
• Mehdi SH, Xu YZ, Shultz LD, [et al., including Kendrick S]. Development of New Diffuse Large B Cell Lymphoma Mouse Models. Cancers. 2024 16(17). PMID: 39272864. PMCID: PMC11394112.
• McCrury M, Swafford K, Shuttleworth SL, [et al., including Kendrick S]. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Molecular cancer therapeutics. 2024 23(3):316-329. PMID: 37816504. PMCID: PMC10932871.
• Chen J, Wang Z, Phuc T, [et al., including Kendrick S]. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLoS pathogens. 2023 19(1):e1011089. PMID: 36638143. PMCID: PMC9879403.
• Swafford K, Acharya B, Xu YZ, [et al., including Kendrick S]. Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group. Genes. 2022 13(7). PMID: 35885931. PMCID: PMC9321325.
• Chen J, Barrett L, Lin Z, [et al., including Kendrick S]. Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target. Journal of cellular and molecular medicine. 2022 26(9):2557-2565. PMID: 35318805. PMCID: PMC9077304.
• Chen J, Dai L, Kendrick S, [et al.]. The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways. Antimicrobial agents and chemotherapy. 2022 66(3):e0239521. PMID: 35041508. PMCID: PMC8923226.
• Mohan M, Kendrick S, Szabo A, [et al.]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2022 6(3):808-817. PMID: 34807986. PMCID: PMC8945288.
• Mohan M, Szabo A, Yarlagadda N, [et al., including Kendrick S]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021 96(9):E341-E344. PMID: 34050985.